Pri-Kanasyn 10
Registered veterinary formulation (DRAP Reg: 079522)
Active: Novaminsulfon USP 40 mg; Etilefrin (as HCl) B.P 0.2 mg; Calcium Gluconate USP 100 mg; Magnesium Gluconate USP 10 mg; Sodium Salicylate B.P 7 mg; Nicotinamide B.P 0.3 mg; Caffeine 10 mg; Boric Acid 10 mg; Each ml injection contains:-; Kanamycin as Sulphate 100 mg
Pri-Kanasyn 10 is a verified injection developed and manufactured by Prix Pharmaceutica Pvt Ltd under strict cGMP protocols. Formulated for Livestock to provide consistent therapeutic efficacy and safety.
Marketed by Prix Pharmaceutica (Pvt) Ltd.
Overview
Pri-Kanasyn 10 is a verified injection developed and manufactured by Prix Pharmaceutica Pvt Ltd under strict cGMP protocols. Formulated for Livestock to provide consistent therapeutic efficacy and safety.
Administration Route
As directed on approved label
Dosage Form
injectable
Explore related Livestock solutions, our full product catalogue, and science and quality standards.
Composition
| Active Ingredient | Strength / Quantity |
|---|---|
| Novaminsulfon USP | 40 mg |
| Etilefrin (as HCl) B.P | 0.2 mg |
| Calcium Gluconate USP | 100 mg |
| Magnesium Gluconate USP | 10 mg |
| Sodium Salicylate B.P | 7 mg |
| Nicotinamide B.P | 0.3 mg |
| Caffeine | 10 mg |
| Boric Acid | 10 mg |
| Kanamycin as Sulphate | 100 mg |
Product information
Detailed product-use information is available from Prix Pharmaceutica technical support and on the approved product label.
For approved use details, please contact our technical team.
Dosage & Administration
Warnings & Precautions
For veterinary use only. Not for human use. Keep out of reach of children.
Withdrawal Period
Storage Instructions
Store below 25°C protected from direct sunlight
Packing
50 ml
Target species
Livestock
Product Documents
Contact Prix Pharmaceutica (Pvt) Ltd. for approved product literature and documentation.
⚠️ Safety Notice
For veterinary use only. Use according to approved product literature and under the guidance of a qualified veterinary professional.
Need guidance?
Our technical team can assist with product selection, dosage and programme development.
Technical Support📞 +92 42 36283464Product Specifications
- Product ID
- PRX-NEW-039
- Life Stages
- Adult, Young stock
- Manufacturing
- Marketed by Prix Pharmaceutica (Pvt) Ltd.
Responsible veterinary use
Product information is provided for professional veterinary reference. Follow the approved product label and consult a qualified veterinarian where appropriate.
Frequently asked questions about Pri-Kanasyn 10
Answers below reflect catalogue information only. Always follow the approved product label and qualified veterinary guidance.
What is Pri-Kanasyn 10?
Which dosage form is available for Pri-Kanasyn 10?
Which pack sizes are listed for Pri-Kanasyn 10?
Which animal category is Pri-Kanasyn 10 listed under?
Where can product information for Pri-Kanasyn 10 be requested?
How should the approved product label be followed?
Who should be consulted before veterinary use?
Related Products
Minerals
Farvisol Bolus
Registered veterinary formulation (DRAP Reg: 075639)
Farvisol Bolus is a verified bolus developed and manufactured by Prix Pharmaceutica Pvt Ltd under strict cGMP protocols. Formulated for Livestock to provide consistent therapeutic efficacy and safety.
Minerals
OXYWAY 5 INJECTION
Registered veterinary formulation (DRAP Reg: 130324)
OXYWAY 5 INJECTION is a verified injection developed and manufactured by PRIX PHARMACEUTICA PVT LTD under strict cGMP protocols. Formulated for Livestock to provide consistent therapeutic efficacy and safety.
Minerals
Pri-Vitoline Forte
Registered veterinary formulation (DRAP Reg: 079250)
Pri-Vitoline Forte is a verified injection developed and manufactured by Prix Pharmaceutica Pvt Ltd under strict cGMP protocols. Formulated for Livestock to provide consistent therapeutic efficacy and safety.
Minerals
Pironil Plus
Registered veterinary formulation (DRAP Reg: 079254)
Pironil Plus is a verified injection developed and manufactured by Prix Pharmaceutica Pvt Ltd under strict cGMP protocols. Formulated for Livestock to provide consistent therapeutic efficacy and safety.
Related insights
- Pakistan Veterinary Pharmaceutical Industry Outlook 2027: Regulatory Modernization, Market Dynamics, and Quality Standards
- Antimicrobial Stewardship in Livestock: Responsible Antibiotic Use, AMR Risks, and Herd Health in Pakistan
- Poultry Respiratory Disease Prevention and Farm Biosecurity in Pakistan: Clinical Insights for Commercial Broilers and Layers